Icarus Medical, a Charlottesville, Virginia medtech company building AI- and additive-manufacturing-driven orthopedic braces, has closed an oversubscribed $7.2 million Series A to accelerate U.S. commercialization of its custom bracing platform.
An oversubscribed round
The round originally targeted $5 million but closed at $7.2 million, which the company attributed to investor confidence in its technology and commercial momentum. Backers include Riptide Ventures, OSF Ventures, the CU Healthcare Innovation Fund, Highpoint Ventures, MedTech Connect, Neovate Capital Partners and BLU Venture Investors. Proceeds will fund commercialization across the United States, continued product development, manufacturing expansion, clinical validation and hiring.
Custom braces, digitally manufactured
Icarus combines biomechanics, software and additive manufacturing to build orthopedic devices for osteoarthritis, post-operative recovery, neurological conditions and lower-extremity mobility challenges. Its flagship Ascender Knee Brace is designed for patients with patellofemoral and multicompartment knee osteoarthritis, using a custom-fit, digitally produced approach to offloading and support.
A busy stretch for rehab and recovery tech
The raise adds to a steady flow of capital and milestones across rehabilitation and recovery hardware, from Fourier's rehabilitation-robotics partnerships to neural-interface programs such as Synchron's Stentrode trial and BrainCo's $286M prosthetics round. Where many of those efforts target implants or powered exoskeletons, Icarus is betting that software-defined, mass-customized bracing can reach far more patients at lower cost.
With the Series A closed, Icarus says its priority is scaling production and clinical evidence for its current devices while expanding its commercial footprint with orthopedic providers across the country.
Reporting based on coverage from PR Newswire, BioSpace and Ortho Spine News.